<DOC>
	<DOCNO>NCT02009397</DOCNO>
	<brief_summary>The purpose study test combination Ipilimumab GM-CSF . Both ipilimumab GM-CSF intend work body 's immune system attack melanoma cell body . This study also demostrate safe combine drug use treat patient Stage 3 Stage 4 melanoma ( metastatic melanoma ) , remove surgery .</brief_summary>
	<brief_title>A Phase I/II Open-Label Study Ipilimumab GM-CSF Administered Unresectable Stage IIIC Stage IV Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients may enter study meet follow criterion . 1 . Male female patient ≥18 year age ; 2 . Patients histological confirm melanoma ( Stage IIIC Stage IV , American Joint Commission Cancer ) ; 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 2 ; 4 . Life expectancy ≥3 month ; 5 . At least 1 site radiographically measurable disease immunerelated response criterion ( irRC ) ; 6 . Adequate hematologic , renal , liver function define laboratory value perform within 42 day prior initiation dosing : Absolute neutrophil count ( ANC ) ≥1.0 x 109/L ; Platelet count ≥50 x 109/L ; Hemoglobin ≥8 g/dL ; Serum creatinine ≤3 x upper limit normal ( ULN ) Total serum bilirubin ≤2 x ULN ; Serum aspartate transaminase ( AST/SGOT ) serum alanine transaminase ( ALT/SGPT ) ≤2x ULN , ≤3 x ULN liver metastases present . 7 . Fertile male use effective method contraception treatment least 3 month completion treatment , direct physician ; 8 . Premenopausal females female &lt; 2 year onset menopause negative pregnancy test Screening . Premenopausal females must agree use acceptable method birth control time negative pregnancy test 90 day last dose study drug . Females nonchildbearing potential may include either surgically sterile postmenopausal ≥1 year ; 9 . Before study entry , write informed consent must obtain patient prior perform studyrelated procedure . Patients enter study follow : 1 . Treatment Denileukin Diftitox within 42 day prior start Ipilimumab ; 2 . Prior treatment Ipilimumab ; 3 . Known hypersensitivity Ipilimumab components 4 . Received radiotherapy non CNS disease within 2 week prior commence study treatment recover side effect radiationrelated toxicity Grade ≤1 , except alopecia ; 5 . Steroids within one week prior initiation Ipilimumab . 6 . Preexisting autoimmune colitis . 7 . Patients allograft require immunosuppression ; 8 . Known positive human immunodeficiency virus ( HIV ) 9 . Pregnant , breastfeeding , refuse double barrier contraception , oral contraceptive , avoidance pregnancy measure ; 10 . Have uncontrolled infection medical condition could interfere conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>